ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
18 announcements with these filters
Sarda Proteins Limited responded to a BSE query regarding recent stock price movement. The company stated the fluctuations are driven by market forces and conditions.
Sarda Proteins Limited has changed its name to Fresita Proteins Limited, effective September 21, 2026. The name change received approval from the Ministry of Corporate Affairs and BSE.
Sarda Proteins Limited filed its 35th Annual Report for the financial year ended 31st March 2026 with the stock exchange.
Sarda Proteins set its 35th AGM for September 30, 2026, with book closure September 24–30. E-voting cut-off date is September 23, 2026.
Sarda Proteins board approved convening its AGM on September 30, 2026, along with e-voting, scrutinizer, and register-closure arrangements. No financial or operational decisions were taken.
Sarda Proteins Limited has scheduled a board meeting for September 7, 2026. The agenda includes approval for the upcoming Annual General Meeting and associated administrative matters.
Sarda Proteins Limited's board approved a Rights Issue of equity shares, with an issue size not exceeding ₹100 Crore. A committee was formed to oversee the process.
Sarda Proteins Ltd reported revenue from operations of ₹0.7 Cr and net profit of ₹0.7 Cr for Q4 FY26.
Sarda Proteins Limited announced designation changes for five directors, including transitions from Additional Director to various board roles, effective July 30, 2026.
Sarda Proteins increased its authorized share capital from 13,000,000 to 100,000,000 equity shares. The change involves an authorized capital restructure approved on July 30, 2026.
Sarda Proteins Ltd has scheduled a board meeting for August 5, 2026. The board will consider a proposal for fund raising through various equity-linked securities.
Sarda Proteins Ltd held an EGM to approve authorised capital increase, company name change to Fresita Proteins Limited, and several director appointments.
Sarda Proteins announced a board and management reshuffle, including the appointment of a new Managing Director and CFO, alongside the resignation of several directors.
Sarda Proteins Limited filed a revised outcome for their July 4, 2026 board meeting. The company additionally approved a change in its corporate name.
Sarda Proteins issued an EGM addendum for July 30, 2026. Agenda items include appointing M/s A H Mandaliya & Associates as auditors and regularizing Ms. Minal Surendra Jain.
Sarda Proteins Limited appointed Ms. Minal Surendra Jain as Non-Executive Independent Director. The appointment is for a five-year term effective July 15, 2026.
Sarda Proteins Ltd reported revenue from operations of ₹13 Cr (+18.2% YoY) and net profit of ₹1.7 Cr for Q1 FY27.
Sarda Proteins scheduled a board meeting on July 15, 2026. The board will consider and approve unaudited financial results for the June quarter.